Manifestaciones cutáneas de la enfermedad inflamatoria intestinal
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
En los últimos años se ha evidenciado un aumento en la incidencia y prevalencia de la enfermedad inflamatoria intestinal, que comprende dos entidades: la enfermedad de Crohn y la colitis ulcerativa. Ambas, y paradójicamente su tratamiento, pueden desencadenar manifestaciones cutáneas con una amplia variedad de manifestaciones clínicas en piel, que son un reto diagnóstico para el médico. Solo el conocimiento de estos fenotipos clínicos permitirá el diagnóstico temprano, con el objetivo de lograr el abordaje diagnóstico y el tratamiento oportunos y de evitar secuelas a largo plazo.
Citas
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-22.
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: A case-control study. Inflamm Bowel Dis 2004;10:207-14.
Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: A study of 700 patients. Medicine (Baltimore) 1976;55:401-12.
Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002;123:714-8.
Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990;98:464-9.
Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011;106:110-9.
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982-92.
Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827-36.
Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Díaz-Rubio M. [Extraintestinal manifestations in inflammatory bowel disease: Differences between Crohn’s disease and ulcerative colitis]. Med Clin (Barc) 2005;125:297-300.
Rankin GB, Watts HD, Melnyk CS, Kelley ML. National Cooperative Crohn’s Disease Study: Extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-20.
Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:307-27.
Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34.
Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:496-505.
Schoepfer AM, Dehlavi M-A, Fournier N, Safroneeva E, Straumann A, Pittet V. Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol 2013;108:1744-53.
Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: Pathophysiology, clinical features, and therapy. Inflamm Bowel Dis 2014;20:213-27.
Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol. 2017;53:413-27.
Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016;10:239-54.
Huang W, McNeely MC. Neutrophilic tissue reactions. Adv Dermatol. 1997;13:33-64.
Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012;86:28-35.
Trikudanathan G, Venkatesh PGK, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72:2333-49.
Galbraith SS, Drolet BA, Kugathasan S, Paller AS, Esterly NB. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics. 2005;116:e439-444.
Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991;78:676-8.
Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J. Extraintestinal manifestations of pediatric inflammatory bowel disease: Prevalence, presentation, and anti-TNF treatment. J Pediatr Gastroenterol Nutr 2017;65:200-6.
Polcz M, Gu J, Florin T. Pyoderma gangrenosum in inflammatory bowel disease: The experience at Mater Health Services’ Adult Hospital 1998-2009. J Crohns Colitis 2011;5:148-51.
Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004;6:88-90.
Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: Characterization of a large North American cohort. Am J Gastroenterol 2006;101:1012-23.
Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn’s disease. Can J Gastroenterol 2005;19:603-6.
Lapidus A, Bernell O, Hellers G, Löfberg R. Clinical course of colorectal Crohn’s disease: A 35- year follow-up study of 507 patients. Gastroenterology 1998;114:1151-60.
Guest GD, Fink RL. Metastatic Crohn’s disease: Case report of an unusual variant and review of the literature. Dis Colon Rectum 2000;43:1764-6.
Lebwohl M, Fleischmajer R, Janowitz H, Present D, Prioleau PG. Metastatic Crohn’s disease. J Am Acad Dermatol 1984;10:33-8.
Hawryluk EB, Izikson L, English JC. Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions. Am J Clin Dermatol 2010;11:171-81.
Burgdorf W. Cutaneous manifestations of Crohn’s disease. J Am Acad Dermatol 1981;5:689-95.
Tweedie JH, McCann BG. Metastatic Crohn’s disease of thigh and forearm. Gut. 1984;25:213-4.
Kafity AA, Pellegrini AE, Fromkes JJ. Metastatic Crohn’s disease. A rare cutaneous manifestation. J Clin Gastroenterol. 1993;17:300-3.
Hoffmann RM, Kruis W. Rare extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:140-7.
Konrad A, Seibold F. Response of cutaneous Crohn’s disease to infliximab and methotrexate. Dig Liver Dis. mayo de 2003;35:351-6.
Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: A cohort study of 2402 patients. Medicine (Baltimore). 2008;87:281-93.
Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: A review of 86 patients. Q J Med. 1985;55:173-86.
Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013;38:563-72.
Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study. Inflamm Bowel Dis 2017;23:1174-81.
Schoch JJ, Tolkachjov SN, Cappel JA, Gibson LE, Davis DMR. Pediatric pyoderma gangrenosum: A retrospective review of clinical features, etiologic associations, and treatment. Pediatr Dermatol 2017;34:39-45.
Ytting H, Vind I, Bang D, Munkholm P. Sweet’s syndrome--an extraintestinal manifestation in inflammatory bowel disease. Digestion 2005;72:195-200.
Ali M, Duerksen DR. Ulcerative colitis and Sweet’s syndrome: A case report and review of the literature. Can J Gastroenterol 2008;22:296-8.
Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26:265-73.
Travis S, Innes N, Davies MG, Daneshmend T, Hughes S. Sweet’s syndrome: An unusual cutaneous feature of Crohn’s disease or ulcerative colitis. Eur J Gastroenterol Hepatol 1997;9:715-20.
Cohen PR, Kurzrock R. Sweet’s syndrome revisited: A review of disease concepts. Int J Dermatol 2003;42:761-78.
Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of greek patients with inflammatory bowel disease. J Crohns Colitis 2016;10:429-36.
Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: Results of a 25-year follow-up study. World J Gastroenterol 2003;9:2300-7.
Apgar JT. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: A selective review. Semin Dermatol 1991;10:138-47.
Weizman A, Huang B, Berel D, Targan SR, Dubinsky M, Fleshner P. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis 2014;20:525-33.
Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: Response to infliximab. J Pediatr Gastroenterol Nutr 2003;37:150-4.
Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2007;21:408-10.
Quin A, Kane S, Ulitsky O. A case of fistulizing Crohn’s disease and erythema nodosum managed with adalimumab. Nat Clin Pract Gastroenterol Hepatol 2008;5:278-81.
Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 2006;31:823-4.
Vavricka SR, Manser CN, Hediger S, Vögelin M, Scharl M, Biedermann L. Periodontitis and gingivitis in inflammatory bowel disease: A case-control study. Inflamm Bowel Dis 2013;19:2768- 77.
Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: Part II. J Am Acad Dermatol 2013;68:211.e1-33.
Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;29:921-7.
Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014;13:15-9.
Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011;34:1318-27.
Rahier J-F, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010;8:1048-55.